NCT03575299

Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells

Clinical Study on Adoptive Treatment of Multidrug Resistant Pulmonary Tuberculosis With Allogeneic γδT Cells

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Zhinan Yin, Ph.D. · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Brief summary: Allogeneic γδT cells from healthy donor will be administrated intravenously to patients with the MDR-TB，and then the safety and efficacy of γδT cells will be evaluated.

Detailed description

All patients with multi-drug resistant pulmonary tuberculosis will be assigned into 2 groups(study group and control group)，both groups will receive conventional treatment. Allogeneic γδT cell will be administrated intravenously to patients in the study group (but not the control group) every two weeks for 6 months

Conditions

• Multi-drug Resistant Tuberculosis

Interventions

Type	Name	Description
BIOLOGICAL	The adoptive treatment of allogeneic γδT cells	Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.
OTHER	Control	No allogeneic γδT cells will be administered to patients with MDR-TB.
DRUG	Conventional treatment	Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.

Timeline

• Start date: 2018-06-01
• Primary completion: 2021-06-30
• Completion: 2021-12-31
• First posted: 2018-07-02
• Last updated: 2018-07-02

Locations

1 site across 1 country: China